Skip to content

Based on the theory of ''spleen governs movement and transformation'' to explore the clinical observation and mechanism study of applying the method of clearing away heat and strengthening spleen to dissipate dampness in the treatment of gouty arthritis

Based on the theory of ''spleen governs movement and transformation'' to explore the clinical observation and mechanism study of applying the method of clearing away heat and strengthening spleen to dissipate dampness in the treatment of gouty arthritis

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005186
Enrollment
Unknown
Registered
2021-08-17
Start date
2021-03-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gouty arthritis

Interventions

Sponsors

The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Comply with the above-mentioned western medicine diagnostic criteria and traditional Chinese medicine diagnostic criteria at the same time, and the syndrome belongs to the accumulation of damp-heat syndrome; (2) Aged 18 to 70 years old with acute phase of gout, and the symptoms reach their peak within 48 hours; (3) not taken other drugs for gouty arthritis at the same time.

Exclusion criteria

Exclusion criteria: (1) The blood uric acid level is lower than the upper limit of the reference range of normal values (200-415umol/L in the reference range of blood uric acid in the Laboratory Department of the Third Affiliated Hospital of Beijing University of Chinese Medicine); (2) Patients who are allergic to NSAIDs drugs; (3) Patients with other rheumatic immune diseases, serious primary diseases such as cardiovascular, liver, kidney, brain, digestive system and hematopoietic system, and mental illness; (4) Those who are severely deformed and incapacitated by advanced arthritis; (5) Pregnant and lactating women; (6) Patients with active gastrointestinal disease, and patients with peptic ulcer within one month before this study; (7) Patients who are currently participating in or have participated in clinical studies of other treatments within 4 weeks before this study.

Design outcomes

Primary

MeasureTime frame
Erythrocyte sedimentation rate;Uric acid;Visual analogue pain score;Musculoskeletal Ultrasound;white blood cell;Serum C-reactive protein;Joint swelling and pain index;

Countries

China

Contacts

Public ContactMa Yufeng

The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine

sheenque@qq.com+86 15801147349

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026